Using a tracer and probe to find meningioma tumor during surgery
Tests whether a tracer injection helps surgeons detect meningioma during surgery in adults.
Key facts
- Who runs it
- Weill Medical College of Cornell University
- Where
- New York, United StatesSee the site
- Trial code
- Registry title
- Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 20 people, planned
- Started
- 11 Sept 2024
- Expected to end
- Jan 2027
- Type of study
- Interventional
- Treatments tested
- Brain Imaging with [Cu64]DOTATATE
- Radio-guided Surgery With Neoprobe Utilization
- Record updated
- 27 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a likely or known meningioma (a tumour of the brain's covering) who need surgery. During surgery, a probe will look for the tumour after an injection of [Cu64]DOTATATE.
- Age
- 18 Years to 99 Years
- Sex
- All sexes can join
- Disease stage
- Meningioma strongly suspected on MRI and needing surgery to remove it. Or meningioma confirmed after earlier surgery, with scans showing tumour that came back or remained and needs another surgery.
- Earlier treatment
- People who had radiation therapy to the head before cannot join.
Main reasons for not taking part
- Pregnant or breastfeeding
- Surgery through the nose, through an eyebrow cut, or any surgery where the neoprobe cannot be used
- Allergy to somatostatin analogs
- Cannot have a usual MRI
- Currently in another treatment trial for meningioma
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- High suspicion of meningioma necessitating surgical resection based on conventional MRI criteria, or diagnosis of meningioma based on pathology reports from prior resection with radiographic findings of suspected recurrent or residual tumor necessitating repeat surgery
Who cannot take part
- Patients undergoing endoscopic endonasal resection, eyebrow incision surgery, or any surgical procedure in which the neoprobe cannot be employed
- Patients with prior history of cranial radiation therapy
- Patients with hypersensitivity to somatostatin analogs
- Pregnant or breastfeeding
- Patients with contraindications to conventional MRI
- Patients currently enrolled in other therapeutic clinical trials related to meningioma will be excluded
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Where in United States
- New York - Presbyterian - Weill Cornell Medical CenterNew York, United StatesContact: Jana Ivanidze, MD/PhDTaking people
About the trial
What the trial wants to find out
The study team hypothesizes that it is feasible to intraoperatively detect tumor following [CU64]DOTATATE injection using the gamma probe device.
The group in the trial
- Patients with MRI findings compatible with meningioma who have an indication for surgeryTreatment being tested
A diagnostic intervention in which patients will undergo intraoperative meningioma tracing using \[Cu64\]DOTATATE.
Treatment: Brain Imaging with [Cu64]DOTATATE and Radio-guided Surgery With Neoprobe Utilization
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Pilot Study to Evaluate Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
- Plain-language title
- Using a tracer and probe to find meningioma tumor during surgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT06377371, who can take part
- Record updated
- 27 February 2026